Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma-induced bone disease

Xin Li; Wen Ling; Bart Barlogie; Shmuel Yaccoby

doi:10.1002/ctm2.70302

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (5) : e70302 DOI: 10.1002/ctm2.70302

LETTER TO THE JOURNAL

Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma-induced bone disease

Author information +

History +

PDF

Cite this article

Download citation ▾

Xin Li, Wen Ling, Bart Barlogie, Shmuel Yaccoby. Induction of HMOX1 by mesenchymal stem cell cytotherapy inhibits osteoclastogenesis and myeloma-induced bone disease. Clinical and Translational Medicine, 2025, 15(5): e70302 DOI:10.1002/ctm2.70302

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol. 2010; 149(3): 311-321.

[2]	Li X, Ling W, Pennisi A, et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells. 2011; 29(2): 263-273.

[3]	Li X, Ling W, Khan S, Yaccoby S. Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth. J Bone Miner Res. 2012; 27(8): 1635-1648.

[4]	Zhou X, Yuan W, Xiong X, et al. HO-1 in bone biology: potential therapeutic strategies for osteoporosis. Front Cell Dev Biol. 2021; 9: 791585.

[5]	Boyce BF, Li J, Yao Z, Xing L. Nuclear factor-kappa B regulation of osteoclastogenesis and osteoblastogenesis. Endocrinol Metab (Seoul). 2023; 38(5): 504-521.

[6]	Omata Y, Tachibana H, Aizaki Y, Mimura T, Sato K. Essentiality of Nfatc1 short isoform in osteoclast differentiation and its self-regulation. Sci Rep. 2023; 13(1): 18797.

[7]	Sakai E, Shimada-Sugawara M, Nishishita K, et al. Suppression of RANKL-dependent heme oxygenase-1 is required for high mobility group box 1 release and osteoclastogenesis. J Cell Biochem. 2012; 113(2): 486-498.

[8]	Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, Yaccoby S. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol. 2007; 138(6): 802-811.

[9]	Danziger SA, McConnell M, Gockley J, et al. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the Total Therapy clinical trials. PLoS Med. 2020; 17(11): e1003323.

[10]	Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014; 124(20): 3043-3051.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.